Dapagliflozin
In acute MI, dapagliflozin confers cardiometabolic benefit, in absence of diabetes, HF
PHILADELPHIA — In patients without diabetes or heart failure presenting with acute MI and impaired left ventricular function, dapagliflozin improved cardiometabolic outcomes compared with placebo, according to the DAPA-MI trial.
Meta-analysis shows SGLT2 inhibitors not beneficial in treating COVID-19
A meta-analysis of three trials assessing the use of SGLT2 inhibitors for inpatients with COVID-19 showed the drug class did not reduce risk for death or other outcomes compared with usual care or placebo, but was safe.
Quadruple therapy borderline cost-effective for HFrEF; drug prices continue to rise
Researchers reported quadruple therapy with SGLT2 and angiotensin receptor-neprilysin inhibition was narrowly cost-effective compared with standard care plus SGLT2 inhibition alone for patients with HF and reduced ejection fraction.
Top news of May: Supreme Court saves alirocumab; mobile phone use and BP; and more
Healio and Cardiology Today have compiled the top cardiology headlines of May 2023.
Top in cardiology: Phone use and high BP risk; expanded indication for dapagliflozin
Greater mobile phone use for making or receiving calls was associated with a higher risk for high blood pressure, particularly in those with a genetic risk for hypertension, recent data show.
FDA expands dapagliflozin indication to include all patients with HF
The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.
Dapagliflozin improves pulmonary capillary wedge pressure during exercise in HFpEF
NEW ORLEANS — Treatment with the SGLT2 inhibitor dapagliflozin for 24 weeks favorably reduced pulmonary capillary wedge pressure at rest and during exercise in adults with HF with preserved ejection fraction vs. placebo, data show.
Dapagliflozin benefits consistent in HF for patients with, without gout
The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with reduced initiation of new treatments for hyperuricemia and gout, according to a post hoc analysis of DAPA-HF and DELIVER.
Cardiology meeting highlights 2022: Results of SPORT, DELIVER trials and more
Healio and Cardiology Today have curated a list of the top cardiology and cardiac/vascular intervention news reported from meetings in 2022.
Dapagliflozin reduces hospitalization risk in adults with chronic kidney disease
The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a post hoc analysis of the DAPA-CKD trial.